JP2010510264A - イオン対マイクロリザーバを含む経皮治療システム - Google Patents
イオン対マイクロリザーバを含む経皮治療システム Download PDFInfo
- Publication number
- JP2010510264A JP2010510264A JP2009537518A JP2009537518A JP2010510264A JP 2010510264 A JP2010510264 A JP 2010510264A JP 2009537518 A JP2009537518 A JP 2009537518A JP 2009537518 A JP2009537518 A JP 2009537518A JP 2010510264 A JP2010510264 A JP 2010510264A
- Authority
- JP
- Japan
- Prior art keywords
- transdermal therapeutic
- therapeutic system
- active ingredient
- additive
- matrix
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7092—Transdermal patches having multiple drug layers or reservoirs, e.g. for obtaining a specific release pattern, or for combining different drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
モキソニジン(2g)及びラウリン酸(10g)を、無水アルコール(50g)中で穏やかに加熱しながら完全に溶解した。この溶液を、n−ヘプタン(200g)中固体ポリシロキサン(200g)の事前調製溶液に加え、そしてパドルスターラーで10分間激しく撹拌した。2相溶液を撹拌しながら、フッ素重合体で表面処理したPETシートの上に約50μmの層厚みにコーティングし、次いで室温で3分間乾燥した。製品は、経皮治療システムに更に処理するのに好適な本発明のマトリックスに相当する。
実施例1で作製された組成物を、微粉末化及び架橋化したポリビニルピロリドン(50g)と混合し、更に約5分間撹拌した。これらの条件下、添加した膨潤性のポリビニルピロリドンの粒径によって規定される内部相マイクロリザーバサイズを形成させ、実施例1と同様に行なったコーティング及び乾燥後にも持続させた。
Claims (11)
- 活性成分−不透過性支持層、及びポリシロキサン及び/又はポリシロキサン誘導体から成る少なくとも1つのマトリックス層を含み、そしてマイクロリザーバ及び剥離可能な活性成分−不透過性保護層を含む経皮治療システムであって、マトリックス内のマイクロリザーバは、1つの薬理活性成分及び1つの添加剤のいずれの組の場合も少なくとも1つのイオン対から成る固体、半固体又は液体内部相を形成し、ここで、添加剤は少なくとも等モル量存在し、また活性成分がカチオン形成体であり添加剤がアニオン形成体であるか、又は活性成分がアニオン形成体であり添加剤がカチオン形成体であるかのいずれかであることを特徴とする経皮治療システム。
- イオン対が物理化学的分子会合の形態で存在することを特徴する、請求項1に記載の経皮治療システム。
- 内部相がマトリックスの少なくとも0.2質量%に相当することを特徴とする、請求項1に記載の経皮治療システム。
- システムが少なくとも1つの膜層を含むことを特徴とする、請求項1に記載の経皮治療システム。
- システムが更なる接着層を含むことを特徴とする、請求項1に記載の経皮治療システム。
- ニコチン、モキソニジン、クロニジン、スコポラミン、アトロピン、ブプレノルフィン、フェンタニル及びその誘導体、サルブタモール又はメマンチンが、カチオン形成活性成分として使用されることを特徴とする、請求項1〜5のいずれか1項に記載の経皮治療システム。
- ジクロフェナク、ケトプロフェン、イブプロフェン、アセチルサリチル酸又はサリチル酸がアニオン形成活性成分として使用されることを特徴とする、請求項1〜5のいずれか1項に記載の経皮治療システム。
- 飽和若しくは不飽和脂肪酸又はその誘導体がアニオン形成添加剤として使用されることを特徴とする、請求項1〜7のいずれか1項に記載の経皮治療システム。
- アミン類がカチオン形成添加剤として使用されることを特徴とする、請求項1〜8のいずれか1項に記載の経皮治療システム。
- ジエタノールアミン、トリエタノールアミン、ジメチルアミノエタノール及び/又はトロメタモールが使用されることを特徴とする、請求項9に記載の経皮治療システム。
- マトリックス層が透過促進剤、可塑剤及び/又は親水性若しくは親油性ポリマーを含むことを特徴とする、請求項1〜10のいずれか1項に記載の経皮治療システム。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102006054732A DE102006054732B4 (de) | 2006-11-21 | 2006-11-21 | Transdermales therapeutisches System mit Ionenpaar-Mikroreservoiren |
DE102006054732.2 | 2006-11-21 | ||
PCT/EP2007/009926 WO2008061677A1 (de) | 2006-11-21 | 2007-11-16 | Transdermales therapeutisches system mit ionenpaar-mikroreservoiren |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014042346A Division JP2014132020A (ja) | 2006-11-21 | 2014-03-05 | イオン対マイクロリザーバを含む経皮治療システム |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2010510264A true JP2010510264A (ja) | 2010-04-02 |
JP5578851B2 JP5578851B2 (ja) | 2014-08-27 |
Family
ID=39106260
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2009537518A Active JP5578851B2 (ja) | 2006-11-21 | 2007-11-16 | イオン対マイクロリザーバを含む経皮治療システム |
JP2014042346A Pending JP2014132020A (ja) | 2006-11-21 | 2014-03-05 | イオン対マイクロリザーバを含む経皮治療システム |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014042346A Pending JP2014132020A (ja) | 2006-11-21 | 2014-03-05 | イオン対マイクロリザーバを含む経皮治療システム |
Country Status (15)
Country | Link |
---|---|
US (1) | US9089527B2 (ja) |
EP (1) | EP2094250B1 (ja) |
JP (2) | JP5578851B2 (ja) |
KR (2) | KR101629516B1 (ja) |
CN (1) | CN101522178B (ja) |
AT (1) | ATE465724T1 (ja) |
AU (1) | AU2007323357A1 (ja) |
BR (1) | BRPI0719093B8 (ja) |
CA (1) | CA2669308A1 (ja) |
DE (2) | DE102006054732B4 (ja) |
ES (1) | ES2340971T3 (ja) |
IL (1) | IL198745A0 (ja) |
MX (1) | MX2009005342A (ja) |
RU (1) | RU2009123366A (ja) |
WO (1) | WO2008061677A1 (ja) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW201338813A (zh) | 2011-12-12 | 2013-10-01 | Lohmann Therapie Syst Lts | 經皮遞送系統 |
DE102011090178A1 (de) * | 2011-12-30 | 2013-07-04 | Lts Lohmann Therapie-Systeme Ag | Transdermales therapeutisches System mit geringer Neigung zur Spontankristallisation |
DE102012213321A1 (de) | 2012-07-30 | 2014-01-30 | Robert Bosch Gmbh | Verfahren und Vorrichtung zum Betreiben eines Fahrzeugs |
US20160008294A1 (en) | 2013-06-04 | 2016-01-14 | Purdue Pharma L.P. | Transdermal delivery system |
US9650338B1 (en) | 2016-07-29 | 2017-05-16 | VDM Biochemicals, Inc. | Opioid antagonist compounds and methods of making and using |
US10238600B2 (en) | 2017-04-13 | 2019-03-26 | Richard C. Fuisz | Package, system and methods for custody and control of drugs, and method and composition for making an oral soluble film, containing at least one active agent |
US9901545B1 (en) | 2017-04-13 | 2018-02-27 | Richard C. Fuisz | Method and composition for making an oral soluble film, containing at least one active agent |
JP7212676B2 (ja) * | 2017-09-04 | 2023-01-25 | エルテーエス ローマン テラピー-ジステーメ アーゲー | 乳化剤を含む経皮送達システム |
CN109432061B (zh) * | 2018-11-09 | 2020-10-30 | 北京德默高科医药技术有限公司 | 含有布洛芬或其结构类似物的多层经皮给药系统 |
Citations (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH09169635A (ja) * | 1995-12-20 | 1997-06-30 | Sekisui Chem Co Ltd | 経皮吸収製剤 |
JPH09315957A (ja) * | 1996-05-28 | 1997-12-09 | Hisamitsu Pharmaceut Co Inc | 経皮治療用装置 |
WO2001005381A1 (fr) * | 1999-07-15 | 2001-01-25 | Hisamitsu Pharmaceutical Co., Inc. | Preparations a absorption percutanee |
JP2001514226A (ja) * | 1997-09-04 | 2001-09-11 | エルティエス ローマン テラピー−ズュステーメ アーゲー | 活性物質スコポラミン基剤(base)を含有する経皮的治療システム |
JP2001518058A (ja) * | 1995-09-29 | 2001-10-09 | スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー | ロピニロールおよびそのアナログの経皮投与 |
JP2002509878A (ja) * | 1998-03-30 | 2002-04-02 | エルティエス ローマン テラピー−ズュステーメ アーゲー | パーキンソン症候群の治療のためのd2−アゴニスト含有経皮吸収治療システムおよびその製造方法 |
JP2002536412A (ja) * | 1999-02-09 | 2002-10-29 | サムヤン コーポレイション | 経皮投与用抗嘔吐剤組成物およびこれを含む製剤 |
JP2003503445A (ja) * | 1999-07-02 | 2003-01-28 | エルテーエス ローマン テラピー−ジステーメ アーゲー | ポリシロキサンおよび両親和性溶媒を基にした微小貯蔵所系 |
JP2005501865A (ja) * | 2001-08-24 | 2005-01-20 | エルテーエス ローマン テラピー−ジステーメ アーゲー | 活性成分フェンタニルを含む経皮治療システム(tts) |
WO2005115355A1 (ja) * | 2004-05-28 | 2005-12-08 | Hisamitsu Pharmaceutical Co., Inc. | 貼付製剤 |
JP2006509759A (ja) * | 2002-11-21 | 2006-03-23 | ファルマシア コーポレーション | パレコキシブ(parecoxib)、バルデコキシブ(valdecoxib)およびベンゾピラン誘導体のような水溶性の選択的シクロオキシゲナーゼ−2阻害剤の経皮投与 |
JP2006232841A (ja) * | 1991-06-27 | 2006-09-07 | Noven Pharmaceuticals Inc | 溶解パラメータに基く薬剤送出系及び薬剤飽和濃度を変化させる方法 |
WO2006093139A1 (ja) * | 2005-02-28 | 2006-09-08 | Hisamitsu Pharmaceutical Co., Inc. | 経皮吸収製剤 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3729299A1 (de) * | 1987-09-02 | 1989-03-23 | Beiersdorf Ag | Transdermales therapeutisches system |
DE3908047A1 (de) * | 1989-03-13 | 1990-09-20 | Desitin Arzneimittel Gmbh | Hochdisperse pharmazeutische zusammensetzung |
US6344211B1 (en) * | 1994-12-24 | 2002-02-05 | Lts Lohmann Therapie-Systeme Gmbh | Transdermal absorption of active substances from subcooled melts |
DE4446600A1 (de) | 1994-12-24 | 1996-06-27 | Lohmann Therapie Syst Lts | Transdermale Resorption von Wirkstoffen aus unterkühlten Schmelzen |
US5968547A (en) * | 1997-02-24 | 1999-10-19 | Euro-Celtique, S.A. | Method of providing sustained analgesia with buprenorphine |
DE19834005A1 (de) * | 1997-09-25 | 1999-04-01 | Lohmann Therapie Syst Lts | Säureadditionssalze von Morphin-Alkaloiden und deren Verwendung |
HUP0003686A3 (en) | 1997-09-25 | 2003-04-28 | Lohmann Therapie Syst Lts | Acidic addition salts of morphine alkaloids and the application thereof |
DE19918105C1 (de) * | 1999-04-22 | 2000-09-21 | Lohmann Therapie Syst Lts | Transdermales therapeutisches System mit einem stark wirksamen Neuroleptikum |
DE10012908B4 (de) * | 2000-03-16 | 2005-03-17 | Lts Lohmann Therapie-Systeme Ag | Stabilisierte übersättigte transdermale therapeutische Matrixsysteme und Verfahren zu ihrer Herstellung |
DE10019311A1 (de) * | 2000-04-19 | 2001-10-31 | Lohmann Therapie Syst Lts | Transdermale therapuetische Systeme zur Applikation von Moxonidin |
US6682757B1 (en) * | 2000-11-16 | 2004-01-27 | Euro-Celtique, S.A. | Titratable dosage transdermal delivery system |
DE10261696A1 (de) * | 2002-12-30 | 2004-07-15 | Schwarz Pharma Ag | Vorrichtung zur transdermalen Verabreichung von Rotigotin-Base |
US20050244485A1 (en) * | 2003-10-14 | 2005-11-03 | Tsung-Min Hsu | Transdermal administration of hydrophilic drugs using a basic permeation enhancer composition |
DE102005010255A1 (de) | 2005-03-07 | 2006-09-14 | Lts Lohmann Therapie-Systeme Ag | Faserfreies transdermales therapeutisches System und Verfahren zu seiner Herstellung |
-
2006
- 2006-11-21 DE DE102006054732A patent/DE102006054732B4/de active Active
-
2007
- 2007-11-16 RU RU2009123366/15A patent/RU2009123366A/ru not_active Application Discontinuation
- 2007-11-16 KR KR1020097010300A patent/KR101629516B1/ko active IP Right Grant
- 2007-11-16 CN CN2007800377256A patent/CN101522178B/zh active Active
- 2007-11-16 US US12/515,769 patent/US9089527B2/en active Active
- 2007-11-16 AU AU2007323357A patent/AU2007323357A1/en not_active Abandoned
- 2007-11-16 EP EP07846633A patent/EP2094250B1/de active Active
- 2007-11-16 BR BRPI0719093A patent/BRPI0719093B8/pt active IP Right Grant
- 2007-11-16 DE DE502007003630T patent/DE502007003630D1/de active Active
- 2007-11-16 AT AT07846633T patent/ATE465724T1/de active
- 2007-11-16 MX MX2009005342A patent/MX2009005342A/es active IP Right Grant
- 2007-11-16 ES ES07846633T patent/ES2340971T3/es active Active
- 2007-11-16 CA CA002669308A patent/CA2669308A1/en not_active Abandoned
- 2007-11-16 JP JP2009537518A patent/JP5578851B2/ja active Active
- 2007-11-16 KR KR1020147010404A patent/KR101525369B1/ko active IP Right Grant
- 2007-11-16 WO PCT/EP2007/009926 patent/WO2008061677A1/de active Application Filing
-
2009
- 2009-05-14 IL IL198745A patent/IL198745A0/en unknown
-
2014
- 2014-03-05 JP JP2014042346A patent/JP2014132020A/ja active Pending
Patent Citations (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006232841A (ja) * | 1991-06-27 | 2006-09-07 | Noven Pharmaceuticals Inc | 溶解パラメータに基く薬剤送出系及び薬剤飽和濃度を変化させる方法 |
JP2001518058A (ja) * | 1995-09-29 | 2001-10-09 | スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー | ロピニロールおよびそのアナログの経皮投与 |
JPH09169635A (ja) * | 1995-12-20 | 1997-06-30 | Sekisui Chem Co Ltd | 経皮吸収製剤 |
JPH09315957A (ja) * | 1996-05-28 | 1997-12-09 | Hisamitsu Pharmaceut Co Inc | 経皮治療用装置 |
JP2001514226A (ja) * | 1997-09-04 | 2001-09-11 | エルティエス ローマン テラピー−ズュステーメ アーゲー | 活性物質スコポラミン基剤(base)を含有する経皮的治療システム |
JP2002509878A (ja) * | 1998-03-30 | 2002-04-02 | エルティエス ローマン テラピー−ズュステーメ アーゲー | パーキンソン症候群の治療のためのd2−アゴニスト含有経皮吸収治療システムおよびその製造方法 |
JP2002536412A (ja) * | 1999-02-09 | 2002-10-29 | サムヤン コーポレイション | 経皮投与用抗嘔吐剤組成物およびこれを含む製剤 |
JP2003503445A (ja) * | 1999-07-02 | 2003-01-28 | エルテーエス ローマン テラピー−ジステーメ アーゲー | ポリシロキサンおよび両親和性溶媒を基にした微小貯蔵所系 |
WO2001005381A1 (fr) * | 1999-07-15 | 2001-01-25 | Hisamitsu Pharmaceutical Co., Inc. | Preparations a absorption percutanee |
JP2005501865A (ja) * | 2001-08-24 | 2005-01-20 | エルテーエス ローマン テラピー−ジステーメ アーゲー | 活性成分フェンタニルを含む経皮治療システム(tts) |
JP2006509759A (ja) * | 2002-11-21 | 2006-03-23 | ファルマシア コーポレーション | パレコキシブ(parecoxib)、バルデコキシブ(valdecoxib)およびベンゾピラン誘導体のような水溶性の選択的シクロオキシゲナーゼ−2阻害剤の経皮投与 |
WO2005115355A1 (ja) * | 2004-05-28 | 2005-12-08 | Hisamitsu Pharmaceutical Co., Inc. | 貼付製剤 |
WO2006093139A1 (ja) * | 2005-02-28 | 2006-09-08 | Hisamitsu Pharmaceutical Co., Inc. | 経皮吸収製剤 |
Also Published As
Publication number | Publication date |
---|---|
BRPI0719093B1 (pt) | 2020-03-24 |
CN101522178B (zh) | 2012-10-03 |
EP2094250A1 (de) | 2009-09-02 |
ES2340971T3 (es) | 2010-06-11 |
DE102006054732A1 (de) | 2008-05-29 |
ATE465724T1 (de) | 2010-05-15 |
CN101522178A (zh) | 2009-09-02 |
KR101629516B1 (ko) | 2016-06-10 |
BRPI0719093B8 (pt) | 2021-05-25 |
US20100112064A1 (en) | 2010-05-06 |
DE102006054732B4 (de) | 2010-12-30 |
CA2669308A1 (en) | 2008-05-29 |
KR101525369B1 (ko) | 2015-06-09 |
BRPI0719093A2 (pt) | 2013-12-03 |
KR20140057398A (ko) | 2014-05-12 |
JP2014132020A (ja) | 2014-07-17 |
RU2009123366A (ru) | 2010-12-27 |
WO2008061677A1 (de) | 2008-05-29 |
JP5578851B2 (ja) | 2014-08-27 |
DE502007003630D1 (de) | 2010-06-10 |
KR20090082412A (ko) | 2009-07-30 |
MX2009005342A (es) | 2009-06-01 |
US9089527B2 (en) | 2015-07-28 |
AU2007323357A1 (en) | 2008-05-29 |
IL198745A0 (en) | 2010-02-17 |
EP2094250B1 (de) | 2010-04-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5578851B2 (ja) | イオン対マイクロリザーバを含む経皮治療システム | |
JP3980633B2 (ja) | エストラジオール浸透強化剤 | |
JP6060213B2 (ja) | 外用医薬組成物を用いた貼付剤 | |
JP2001517696A (ja) | ジクロフェナクジエチルアンモニウム塩を含む、抗炎症鎮痛用経皮ドラッグデリバリーシステム、及びその製造方法 | |
TW201206480A (en) | Skin irritation suppressant and transdermal preparation | |
PT813865E (pt) | Penso com ingrediente activo | |
PH27001A (en) | Transdermal monolith system | |
WO1992020377A1 (en) | Skin permeation enhancer compositions using glycerol monolinoleate | |
TW201431572A (zh) | 荷爾蒙及其它醫藥劑之經皮傳遞的組成物及方法 | |
JP2002332228A (ja) | 経皮吸収貼付剤およびその製造方法 | |
WO2005102306A1 (ja) | 消炎鎮痛貼付剤 | |
JP3193161B2 (ja) | 経皮吸収性製剤 | |
CA2121991A1 (en) | Butyrophenone transdermal compositions | |
EP2371360B1 (en) | Selegiline-containing adhesive preparation | |
TW201223528A (en) | Transdermal absorption preparation | |
JPS63203613A (ja) | 親水性経皮投与製剤 | |
JPS6066759A (ja) | 医薬製剤 | |
JP3268406B2 (ja) | 外用テープ剤 | |
JP3548195B2 (ja) | 経皮吸収型製剤 | |
JPH06279288A (ja) | パップ剤 | |
JPH08277229A (ja) | 経皮吸収促進剤および経皮吸収型製剤 | |
JPH07116024B2 (ja) | 硬膏剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20101005 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20121018 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20121120 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20130219 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20130226 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130515 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20130515 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20131105 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140305 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20140415 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20140701 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20140708 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5578851 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |